Adherence and Risk Behaviour in Patients With HIV Infection Receiving Antiretroviral Therapy (ARB)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00511056 |
Recruitment Status
:
Completed
First Posted
: August 3, 2007
Last Update Posted
: July 11, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Study Hypothesis: Do certain risk behaviours impact/predict levels of HIV antiretroviral adherence?
Objectives:
- To assess risk behavior in HIV-positive individuals receiving highly active antiretroviral therapy.(HAART)
- To assess levels of adherence in the same subjects at the same time point
- To determine if there is a correlation between HAART adherence and risk behaviour
Condition or disease |
---|
HIV Infections |

Study Type : | Observational |
Actual Enrollment : | 700 participants |
Observational Model: | Cohort |
Time Perspective: | Cross-Sectional |
Official Title: | Adherence and Risk Behaviour in Patients With HIV Infection Receiving Antiretroviral Therapy |
Study Start Date : | September 2007 |
Actual Primary Completion Date : | January 2009 |
Actual Study Completion Date : | December 2009 |

Group/Cohort |
---|
HIVNAT 006
HIVNAT 006 is a long term follow up cohort. The primary objective of this study is to collect and evaluate the long-term clinical outcomes of HIV infected patients have participated in HIV-NAT studies. These subjects will be used to test our hypothesis.
|
- The relationship between sexual risk behavior and adherence to HIV medications and how do these behaviors relate to patient beliefs about HIV transmission. [ Time Frame: 2 Years ]
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Age ≥ 18 years
- HIV seropositive.
- On continuous HAART for at least 6 months
- Signed written informed consent

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00511056
Thailand | |
HIV-NAT, Thai Red Cross AIDS Research Centre | |
Bangkok, Thailand, 10330 |
Principal Investigator: | Kiat Ruxrungtham, M.D., M.Sc. | HIVNAT |
Additional Information:
Publications of Results:
Responsible Party: | Dr Kiat Ruxrungtham, The HIV Netherlands Australia Thailand Research Collaboration |
ClinicalTrials.gov Identifier: | NCT00511056 History of Changes |
Other Study ID Numbers: |
HIV-NAT Amendment II to 006 |
First Posted: | August 3, 2007 Key Record Dates |
Last Update Posted: | July 11, 2011 |
Last Verified: | July 2011 |
Keywords provided by The HIV Netherlands Australia Thailand Research Collaboration:
HIV Adherence Compliance Highly Active Antiretroviral Therapy (HAART) ARV |
ART Sexual Risk Behavior Unsafe Transmission |
Additional relevant MeSH terms:
Infection Communicable Diseases HIV Infections Acquired Immunodeficiency Syndrome Lentivirus Infections Retroviridae Infections RNA Virus Infections |
Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases |